Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes

Cancer Research

Volumn 74, Issue 21, 2014, Pages 6022-6035

  Kanterman, Julia ^a   Sade Feldman, Moshe ^a   Biton, Moshe ^a   Ish Shalom, Eliran ^a   Lasry, Audrey ^a   Goldshtein, Aviya ^a   Hubert, Ayala ^b   Baniyash, Michal ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD247 ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LYMPHOCYTE ANTIGEN; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL DIFFERENTIATION; CELL ISOLATION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MORTALITY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOLOGICAL BLOCKING; POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MICE; MYELOID CELLS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84909608106     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0657     Document Type: Article

References (34)

1. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-14.e5.
2. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 2013;8:e57114.
3. Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ, et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol 2012;18:3303-9.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7.
5. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013;19:57-64.
6. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 2009;85:996-1004.
7. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloidderived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235-49.
8. Kanterman J, Sade-Feldman M, Baniyash M. Newinsights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 2012; 22:307-18.
9. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumorinduced myeloid-derived suppressor cells. J Immunol 2009;182: 5693-701.
10. Ramakrishnan R, Gabrilovich DI. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother 2011;60:419-23.
11. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 1973;288: 998-1006.
12. Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM. Costeffectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 2005;104:1871-84.
13. Nelson MA, Shetty S, Kulakodlu M, Harley C, Seal B. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. J Med Econ 2011;14:179-86.
14. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
15. Vaknin I, Blinder L, Wang L, Gazit R, Shapira E, Genina O, et al. A common pathway mediated through Toll-like receptors leads to T-and natural killer-cell immunosuppression. Blood 2008;111:1437-47.
16. Popivanova BK, Kitamura K,WuY, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008;118:560-70.
17. Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 2013;38:541-54.
18. Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A, et al. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 2006;177:4763-72.
19. Drakes ML, Czinn SJ, Blanchard TG. Isolation and purification of colon lamina propria dendritic cells from mice with colitis. Cytotechnology 2004;46:151-61.
20. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T-cell-dependent antitumor immunity. Cancer Res 2010;70:3052-61.
21. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog 2011;10:9.
22. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008;181:4666-75.
23. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008;14:3937-47.
24. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol 2012;18:3839-48.
25. Jawad N, Direkze N, Leedham SJ. Inflammatory bowel disease and colon cancer. Recent Results Cancer Res 2011;185:99-115.
26. Kodumudi KN,WoanK, Gilvary DL, Sahakian E, Wei S, Djeu JY.Anovel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16:4583-94.
27. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
28. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011;9:133-48.
29. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
30. Van Deventer HW, Burgents JE, Wu QP, Woodford RM, Brickey WJ, McElvania-Tekippe E, et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumorassociated myeloid-derived suppressor cells. Cancer Res 2010;24: 10161-9.
31. O'Sullivan BJ, ThomasHE, Pai S, Santamaria P, Iwakura Y, Steptoe RJ, et al. IL-1 beta breaks tolerance through expansion of CD25+ effector T-cells. J Immunol 2006;176:7278-87.
32. Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother 2013;63:11-20.
33. Lipson EJ. Re-orienting the immune system: durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology 2013;2:e23661.
34. Noguchi T, Ritter G, Nishikawa H. Antibody-based therapy in colorectal cancer. Immunotherapy 2013;5:533-45.